Risk of metabolic syndrome in patients with bipolar disorder in Türkiye: A one-year follow-up study

Abstract

Objective

This study examined the incidence of metabolic syndrome (MetS) in individuals with bipolar disorder (BD) and identified clinical and biological predictors of incident MetS during a 1-year follow-up.

Methods

The study included 100 euthymic BD type-1 patients consecutively recruited from outpatient clinics between July 2023 and July 2024. MetS was defined according to International Diabetes Federation criteria. Patients without MetS at baseline but with MetS during follow-up were classified as having incident MetS. A logistic regression model was utilized to estimate the adjusted odds ratios (OR) and corresponding 95% confidence intervals (CIs) for associations between predictors and incident MetS.

Results

Of the participants enrolled in the study (n = 100, 92% response rate), 29% met MetS criteria at baseline. Of the 71 without baseline MetS, 29 (40.8%) developed MetS over a 1-year period. Significant predictors of MetS onset included a higher number of manic/hypomanic episodes (OR = 1.459, 95% CI = 1.005-2.118, P = .047), increased chlorpromazine-equivalent antipsychotic dosages (OR = 1.007, 95% CI = 1.001-1.013, P = .024), high waist circumference (OR = 1.247, 95% CI = 1.052-1.479, P = .011), and hypertriglyceridemia (OR = 1.041, 95% CI = 1.007-1.077, P = .020). Conversely, lamotrigine use was inversely associated with MetS development (OR = 0.030, 95% CI = 0.001-0.659, P = .026).

Conclusion

A high incidence of MetS (41%) was observed during a 1-year follow-up of patients with BD in Turkey. Identified risk factors highlight opportunities for intervention through mood recurrence prevention, careful pharmacotherapy management, and treatment of pre-existing components of MetS.

Keywords

bipolar disorders longitudinal metabolic syndrome antipsychotics

Get full access to this article

View all access options for this article.

References

Merikangas

Jin

J-P

, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241-251.

Godin

Etain

Henry

, et al. Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry. 2014;75:1078-1085.

Godin

Olié

Fond

, et al. Incidence and predictors of metabolic syndrome onset in individuals with bipolar disorders: a longitudinal study from the FACE‐BD cohort. Acta Psychiatr Scand. 2024;149:207-218.

Paljärvi

Herttua

Taipale

Lähteenvuo

Tanskanen

Tiihonen

. Cardiovascular mortality in bipolar disorder: population-based cohort study. Acta Psychiatr Scand. 2024;150:56-64.

de Girolamo

La Cascia

Macchia

, et al. Metabolic Syndrome in people treated with Antipsychotics (RISKMet): a multimethod study protocol investigating genetic, behavioural, and environmental risk factors. PLoS One. 2024;19:e0298161.

Ford

. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769-1778.

Grover

Mehra

Chakravarty

Jagota

Sahoo

. Change in prevalence of metabolic syndrome in patients with bipolar disorder. Asian J Psychiatr. 2020;47:101876.

Vancampfort

Stubbs

Mitchell

, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis. World Psychiatry. 2015;14:339-347.

Vancampfort

Vansteelandt

Correll

, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170:265-274.

10.

Westman

Hällgren

Wahlbeck

Erlinge

Alfredsson

Osby

. Cardiovascular mortality in bipolar disorder: a population-based cohort study in Sweden. BMJ Open. 2013;3:e002373.

11.

Bond

Torres

Lee

, et al. Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12‐month study. Acta Psychiatr Scand. 2017;135:239-249.

12.

Giménez-Palomo

Gomes-da-Costa

Dodd

, et al. Does metabolic syndrome or its component factors alter the course of bipolar disorder? A systematic review. Neurosci Biobehav Rev. 2022;132:142-153.

13.

Fagiolini

Frank

Scott

Turkin

Kupfer

. Metabolic syndrome in bipolar disorder: findings from the bipolar disorder center for Pennsylvanians. Bipolar Disord. 2005;7:424-430.

14.

Grundy

Cleeman

Daniels

, et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation. 2005;112:2735-2752.

15.

Alberti

KGM

Zimmet

Shaw

IDF Epidemiology Task Force Consensus Group . The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059-1062.

16.

Alberti

Eckel

Grundy

, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120:1640-1645.

17.

Salvi

D’Ambrosio

Bogetto

Maina

. Metabolic syndrome in Italian patients with bipolar disorder: a 2-year follow-up study. J Affect Disord. 2012;136:599-603.

18.

Malhotra

Kulhara

Chakrabarti

Grover

. A prospective, longitudinal study of metabolic syndrome in patients with bipolar disorder and schizophrenia. J Affect Disord. 2013;150:653-658.

19.

First

Williams

Karg

, et al. Structured clinical interview for DSM-5 disorders. Clinician version (SCID-5-CV). Washington DC: American Psychiatric Association, 2015.

20.

Young

Biggs

Ziegler

Meyer

. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.

21.

Hamilton

. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.

22.

Tao

Shen

Zhou

Sun

Jin

. A systematic review and meta-analysis of metabolic syndrome prevalence in Chinese inpatients with bipolar disorder. Horm Metab Res. 2022;54:587-592.

23.

Zila-Velasque

Grados-Espinoza

Challapa-Mamani

, et al. Prevalence of metabolic syndrome and its components according to altitude levels: a systematic review and meta-analysis. Sci Rep. 2024;14:27581.

24.

World Health Organization . WHO European Regional Obesity Report 2022. Copenhagen: World Health Organization; 2022.

25.

Erem

. Prevalence of overweight and obesity in Turkey. IJC Metab Endocr. 2015;8:38-41.

26.

Gogas Yavuz

Akhtar

Low

, et al. The economic impact of obesity in Turkey: a micro-costing analysis. Clinicoecon Outcomes Res. 2024;16:123-132.

27.

Moreira

Jansen

Cardoso

, et al. Metabolic syndrome in subjects with bipolar disorder and major depressive disorder in a current depressive episode: population-based study: metabolic syndrome in current depressive episode. J Psychiatr Res. 2017;92:119-123.

28.

Fusar-Poli

Amerio

Cimpoesu

, et al. Lipid and glycemic profiles in patients with bipolar disorder: cholesterol levels are reduced in mania. Medicina (Kaunas). 2020;57:28.

29.

Shapiro

Kennedy

Dimick

Goldstein

. Elevated atherogenic lipid profile in youth with bipolar disorder during euthymia and hypomanic/mixed but not depressive states. J Psychosom Res. 2022;156:110763.

30.

Campbell

. The metabolic overdrive hypothesis: hyperglycolysis and glutaminolysis in bipolar mania. Mol Psychiatry. 2024;29:1521-1527.

31.

Rowland

Perry

Upthegrove

, et al. Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses. Br J Psychiatry. 2018;213:514-525.

32.

Pillinger

McCutcheon

Vano

, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64-77.

33.

Grootens

Meijer

Hartong

, et al. Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder. Eur J Clin Pharmacol. 2018;74:1485-1489.

34.

Guerdjikova

McElroy

Welge

Nelson

Keck

Hudson

. Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol. 2009;24:150-158.

35.

Yamamoto

Kanahara

Hirai

Watanabe

Iyo

. Lamotrigine in binge-eating disorder associated with bipolar II depression and treatment-resistant type 2 diabetes mellitus: a case report. Clin Neuropharmacol. 2013;36:34-35.

36.

Nestsiarovich

Kerner

Mazurie

, et al. Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder. Psychoneuroendocrinology. 2020;112:104511.

37.

Grover

Aggarwal

Dutt

, et al. Prevalence of metabolic syndrome in patients with schizophrenia in India. Psychiatry Res. 2012;200:1035-1037.